Skip to content
value.today

SeaStar Medical Holding Corporation

ICU
$12 Mmarket cap on Oct 30, 2026-44.2% since Jan 2024
Compare
World rank
#25,517
Revenue
$1 M
For year ending December-2025
Net income
$-12 M
-987.8% margin
SEC filing
Employees
17
As of December 31, 2025
SEC filing

SeaStar Medical Holding Corporation in brief

SeaStar Medical Holding Corporation is a listed company in the Shell Companies industry, based in Denver, Colorado, USA. Its market value was $12 M on 30 October 2026, which makes it the 25,517th largest listed company in the world and the 4,255th largest in the USA on this site. In the year to December 2025 it had sales of $1 M and a net loss of $12 M. It employs about 17 people and Eric Schlorff is its chief executive. Its largest product and service lines by sales in 2025 were Pediatric SCDs (97%). Its shares trade under the symbol ICU (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About SeaStar Medical Holding Corporation

We are a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life. Our Selective Cytopheretic Device is designed as a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation and creates a cascade of events that wreak havoc in the patient’s body. It has broad potential applications for patients suffering from both acute and chronic kidney disease as well as cardiovascular and other serious inflammatory diseases.

We received Food and Drug Administration approval on February 21, 2024, under a Humanitarian Device Exemption for our pediatric SCD therapy. It is the only FDA approved product for use in pediatric patients with acute kidney injury due to sepsis or a septic condition requiring kidney replacement therapy. We shipped our first commercial pediatric SCD in July 2024. In addition, we are currently conducting a pivotal clinical trial, also referred to as "NEUTRALIZE-AKI" to assess the safety and efficacy of the SCD therapy in critically ill adult patients with AKI requiring continuous renal replacement therapy. We are also conducting a feasibility study of the SCD therapy in adult patients with Cardiorenal Syndrome awaiting left ventricular assist device implantation.

From the company's annual report filed with the US SEC: read the report

SeaStar Medical Holding Corporation timeline

4 events, 2020–2022
  1. 2020
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2021
  4. 🔔
    · approximate
    Initial public offering on Nasdaq
  5. 🔔
    Initial public offering as LMF Acquisition Opportunities Inc
    Final prospectus filed with the SEC on 27 January 2021; shares registered for exchange trading on 22 January 2021. The blank-check company later merged with the business that carries the name today.
  6. 2022
  7. ✎
    Renamed SeaStar Medical Holding Corp
    Formerly LMF Acquisition Opportunities Inc.

Events of SeaStar Medical Holding Corporation from SEC EDGAR and the company record. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$14 M$28 M$41 M$55 M2023202420252026

World rank over time

▼ down 436 places since 2022
2022-12-25: #25089#25,08920222023-07-30: #31709#31,70920232024-01-05: #28572#28,57220242026-03-08: #12816#12,81620262026-08-01: #22496#22,49620262026-10-09: #24562#24,56220262026-10-30: #25525#25,5252026

Rank in USA: #4,762 (Dec 2022) · #5,458 (Jul 2023) · #4,334 (Jan 2024) · #2,390 (Mar 2026) · #3,998 (Aug 2026) · #4,127 (Oct 2026) · #4,256 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
5.6×
Price / book
1.2×
Free cash flow yield
—
Net margin (TTM)
-673.9%
Operating margin
-990.2%
Return on equity
-141.0%
Liabilities / assets
26.4%
Net debt
$4M
Revenue growth
+778.6%
R&D / revenue
611.4%
Revenue per employee
$72 K
Profit per employee
$-715 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2021: revenue —, net income $-5M—FY21Fiscal year ending Dec 2022: revenue —, net income $-12M—FY22Fiscal year ending Dec 2023: revenue —, net income $-26M—FY23Fiscal year ending Dec 2024: revenue $0M, net income $-25M$0MFY24Fiscal year ending Dec 2025: revenue $1M, net income $-12M$1MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$1M+778.6%$-12M$-12M-987.8%
Dec 2024$0M—$-18M$-25M-17735.7%
Dec 2023——$-14M$-26M—
Dec 2022——$-12M$-12M—
Dec 2021——$-4M$-5M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-14M————
Dec 2024$-16M——$-6.63—
Dec 2023$-10M——$-30.26—
Dec 2022$-8M——$-1.48—
Dec 2021$-5M——$-0.63—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$2M
Net income, trailing 12 months
$-15M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-4M—Dec ’24Three months to Mar 2025: revenue $0M, net income $-4M$0MMar ’25Three months to Jun 2025: revenue $0M, net income $-2M$0MJun ’25Three months to Sep 2025: revenue $0M, net income $-3M$0MSep ’25Three months to Dec 2025 (from the annual report): revenue $0M, net income $-3M$0MDec ’25Three months to Mar 2026: revenue $1M, net income $-4M$1MMar ’26Three months to Jun 2026: revenue $1M, net income $-4M$1MJun ’26Three months to Sep 2026: revenue $1M, net income $-5M$1MSep ’26

Latest quarter to Sep 2026: revenue $1M (+255.6% on a year earlier), net income $-5M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of SeaStar Medical Holding Corporation with the US Securities and Exchange Commission.

Annual results

Revenue
$1 M
Operating income
$-12 M
Net income
$-12 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$14 M
Total liabilities
$4 M
Total equity
$10 M

As of December-2025

Top 21 institutional investors in SeaStar Medical Holding Corporation#

As of Sep 30, 2026
21 institutions held 221,880 shares (about 4.2% of the shares outstanding) on Sep 30, 2026. The ten largest hold 4.2%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 21 largest institutional investors in SeaStar Medical Holding Corporation
#InstitutionShares heldChange (shares)% heldValueFiled
1LPL Financial LLC66,801New1.26%$0 MNov 6, 2026
2Geode Capital Management, LLC51,009+1,416 (+2.86%)0.96%$0 MNov 6, 2026
3Vanguard Capital Management LLC33,0910 (0.00%)0.62%$0 MNov 13, 2026
4UBS Group AG26,614-4,784 (-15.24%)0.50%$0 MNov 10, 2026
5Vanguard Fiduciary Trust Co13,6920 (0.00%)0.26%$0 MNov 13, 2026
6HRT Financial LP12,579New0.24%$0 MNov 13, 2026
7Northern Trust Corp10,4020 (0.00%)0.20%$0 MNov 16, 2026
8PNC Financial Services Group, Inc.4,9430 (0.00%)0.09%$0 MNov 6, 2026
9BlackRock, Inc.9130 (0.00%)0.02%$0 MNov 13, 2026
10Barclays PLC633+629 (+15725.00%)0.01%$0 MNov 6, 2026
11Tower Research Capital LLC (TRC)565-791 (-58.33%)0.01%$0 MNov 16, 2026
12Osaic Holdings, Inc.1950 (0.00%)0.00%$0 MNov 12, 2026
13NewEdge Advisors, LLC1760 (0.00%)0.00%$0 MNov 13, 2026
14Vanguard Global Advisers, LLC1650 (0.00%)0.00%$0 MNov 13, 2026
15Fifth Third Bancorp50New0.00%$0 MNov 5, 2026
16TD Waterhouse Canada Inc.220 (0.00%)0.00%$0 MOct 16, 2026
17SBI Securities Co., Ltd.140 (0.00%)0.00%$0 MOct 22, 2026
18SOA Wealth Advisors, LLC.60 (0.00%)0.00%$0 MNov 10, 2026
19Wells Fargo & Company/mn4New0.00%$0 MNov 16, 2026
20Caitong International Asset Management Co., Ltd4+2 (+100.00%)0.00%$0 MOct 29, 2026
21HighMark Wealth Management LLC20 (0.00%)0.00%$0 MNov 17, 2026

Mutual funds holding SeaStar Medical Holding Corporation#

6 funds hold shares worth $0 M (about 1.4% of the company). Since their previous reports 4 added shares and 1 sold, buying $0 M net.
Mutual funds holding SeaStar Medical Holding Corporation
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.33,091$0 M0.62%<0.01%+39%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC21,929$0 M0.41%<0.01%−1.4%May 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC8,656$0 M0.16%<0.01%+291%May 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC5,814$0 M0.11%<0.01%+46%May 31, 2026
🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP2,835$0 M0.05%<0.01%newJul 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC447$0 M<0.01%<0.01%no changeMay 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 6 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at SeaStar Medical Holding Corporation#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$17 K
5 purchases, 3 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$17 K
open market only
Insiders on file
19
since
$80 K$0Nov 2023: bought $40 K (1 trades), sold $0 (0 trades)Nov 23Jun 2024: bought $80 K (2 trades), sold $0 (0 trades)Aug 2024: bought $52 K (1 trades), sold $0 (0 trades)AugSep 2024: bought $4 K (1 trades), sold $0 (0 trades)Nov 2024: bought $8 K (1 trades), sold $0 (0 trades)NovDec 2024: bought $20 K (1 trades), sold $0 (0 trades)May 2025: bought $18 K (2 trades), sold $0 (0 trades)MayJun 2025: bought $19 K (2 trades), sold $0 (0 trades)Aug 2025: bought $39 K (3 trades), sold $0 (0 trades)AugDec 2025: bought $6 K (2 trades), sold $0 (0 trades)Aug 2026: bought $2 K (1 trades), sold $0 (0 trades)AugNov 2026: bought $9 K (2 trades), sold $0 (0 trades)
Bought (open market)Sold (open market)Hover a month for the totals
SeaStar Medical Holding Corporation: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Kevin ChungChief Medical OfficerBuy+7,800$0.845$7 K35,821Form 4
filed Michael MessingerChief Financial OfficerBuy+2,500$0.850$2 K5,000Form 4
filed Michael MessingerChief Financial OfficerBuy+750$3.270$2 K2,500Form 4
filed Kevin ChungChief Medical OfficerGrant or award+7,202——28,021Form 4
filed Bernadette N. VincentDirectorGrant or award+4,000——8,200Form 4
filed Kenneth Van HeelDirectorGrant or award+4,000——11,940Form 4
filed Eric SchlorffChief Executive OfficerGrant or award+10,288——50,140Form 4
filed Jennifer A. BairdDirectorGrant or award+4,000——10,620Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: SeaStar Medical Holding Corporation#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
175,168
4.6% of shares · 1.33 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-25 reverse split

Trading halts

  • 2026-01-03 00:50 UTC, code T3, resumed 14:00 UTC

Fails to deliver

  • : 243 shares at $2.31
  • : 2,592 shares at $3.06
  • : 44,694 shares at $3.49
  • : 151,970 shares at $3.72
  • : 30,068 shares at $3.19

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

SeaStar Medical Holding Corporation scorecard#

Passes 4 of the 12 checks that could be worked out: strongest in valuation (2 of 4), weakest in profitability (0 of 4). Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation2 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median1.2×Price to book 1.2× against Shell Companies's median of 2.0×.
    • ✓Price to sales below its peers' median5.6×Price to sales 5.6× against Shell Companies's median of 5.7×.
    • –Free cash flow yield above 5%No free cash flow yield on file.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth1 of 1
    • ✓Revenue grew in the newest year778.6%Revenue up 778.6% in fiscal 2025.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
    • –Net income higher than five years earlierNet income of five years earlier is not on file.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 4
    • ✗Profitable in the newest year-$12 MNet income -$12 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-990.2%-990.2% against Shell Companies's median of -141.8% (5 companies).
    • ✗Return on equity above 15%-294.9%-294.9% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 3
    • ✓Short-term assets cover short-term liabilities3.6×Current ratio 3.63 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-14.95Z-score -14.95 (distress zone) for fiscal 2025.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Shell Companies, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from SeaStar Medical Holding Corporation's statements, beside the median of Shell Companies.

SeaStar Medical Holding Corporation: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-990.2%-141.8%
Net margin-987.8%-90.5%
Return on equity-294.9%-29.6%
Revenue growth778.6%12.6%

3of 8on the Piotroski tests of financial strength

  • Net loss of $12 million, the 5th loss-making year in a row.

SeaStar Medical Holding Corporation: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

SeaStar Medical Holding Corporation: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021
Income statement
Revenue1.20.10——
Cost of revenue0.100——
Gross profit1.20.10——
Research and development7.59.16.02.5r2.8
General and administrative5.88.98.26.9r1.7r
Operating expenses131814124.4
Operating income−12−18−14−12−4.4r
Interest and finance income0.30.10—0.0
Interest expense and finance costs0.00.21.10.60.2
Other non-operating income (expense)0.0−7.0−12−0.6r−0.1
Income before tax−12−25−26−12r−4.6
Income tax0.00.000.0−0.0
Net income including minority interests—−25−26−12r−4.6r
Net income attributable to shareholders−12−25−26−12r−4.6r
Earnings per share, basic-5.86-66.33r-30.26r-1.48r-0.63
Earnings per share, diluted—-6.63-30.26r-1.48r-0.63
Shares, weighted average (basic)2.10.4r0.9r8.27.2
Shares, weighted average (diluted)—3.70.9r8.27.2
Balance sheet
Cash and cash equivalents121.80.20.00.1
Receivables0.20.10——
Inventory0.10———
Current assets143.82.31.5r0.6r
Total assets144.73.53.0r0.6r
Accounts payable0.93.04.41.90.1r
Debt due within a year—0.60.61.2—
Current liabilities3.76.81316r3.1r
Total liabilities3.76.81724r3.4r
Retained earnings−152−140−115−89r−76r
Shareholders' equity10−2.2−14−21r−2.8r
Total liabilities and equity144.73.53.0r0.6r
Shares outstanding3.80.7r2.0r13—
Cash-flow statement
Share-based compensation0.60.91.91.30.0
Cash from operating activities−14−16−10−7.8−5.1r
Cash from investing activities————−106
Debt issued—1.1———
Shares issued16174.70—
Cash from financing activities2418107.32.8r
Change in cash101.6———
Report10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What SeaStar Medical Holding Corporation sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Pediatric SCDs$1 M97%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Events at SeaStar Medical Holding Corporation#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Delisting noticeFiling

Delisting notice 2 · Acquisition or sale completed 1 · Directors and officers 7 · Material agreement 3 · Unregistered share sale 3 · Shareholder rights changed 2 · Shareholder vote 3 · Results announced 6

SeaStar Medical Holding Corporation: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Material agreementUnregistered share sale8-K
Results announced8-K
Directors and officers8-K
Directors and officers8-K/A
Directors and officersShareholder vote8-K
Results announced8-K
Results announced8-K
Shareholder rights changed8-K/A
Shareholder rights changedShareholder vote8-K
Directors and officers8-K
Results announced8-K
Directors and officers8-K
Directors and officers8-K
Results announced8-K/A
Acquisition or sale completed8-K
Delisting notice8-K
Delisting notice8-K/A
Material agreementUnregistered share sale8-K
Directors and officers8-K
Material agreementUnregistered share sale8-K
Shareholder vote8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

Private share sales · funding history

Private share sales of SeaStar Medical Holding Corporation
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2026$3 MPrivate placement after listing$2 to $10 million3optionsSEC
Jul 2024$10 MPrivate placement after listing$10 to $50 million4equity, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

How SeaStar Medical Holding Corporation compares in Shell Companies

  • Market cap$12 M · higher than 15% of 61
  • Revenue$1 M · higher than 72% of 59
  • Net margin-673.9% · higher than 6% of 17
  • Revenue growth778.6% · higher than 90% of 22
  • Price / sales5.6× · lower than 47% of 16
  • Price / book1.2× · lower than 54% of 14

Peer comparison · Shell Companies

CompanyMarket capP/ENet marginRev. growth
SeaStar Medical Holding Corporation🇺🇸$12 M—-673.9%+778.6%
Oklo Inc.🇺🇸$5.2 B———
Core Scientific Inc.🇺🇸$4.6 B—-18.3%-37.5%
2MX Organic S.A.🇫🇷$1.3 B———
Corner Growth Acquisition Corp. 2🇺🇸$721 M450.6×——
Sable Offshore Corp.🇺🇸$599 M———
Solid Power, Inc.🇺🇸$456 M—-429.5%+8.0%
Orchestra BioMed Holdings, Inc.🇺🇸$444 M—-182.5%+1168.2%
M3-Brigade Acquisition ii Corp.🇺🇸$442 M———

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at SeaStar Medical Holding Corporation? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show SeaStar Medical Holding Corporation's ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about SeaStar Medical Holding Corporation? Suggest a correction